Embodiments may provide self-guided, self-directed diagnostics and treatment of neural conditions. For example, a system may comprise a processor, memory accessible by the processor, and program instructions and data stored in the memory, a plurality of stimulation devices connected to signal output circuitry interfacing the processor with the stimulation devices, program instructions and data to control the stimulation devices to generate and transmit stimulation signals, a plurality of sensing devices connected to signal input circuitry interfacing the processor with the sensing devices, program instructions and data to receive sensed signals from the sensing devices, a communication device adapted to wirelessly communicate with a server computer system, and program instructions and data to perform dynamic closed loop feedback of the stimulation signals based on the received sensed signals to provide self-guided, self-directed diagnostics and treatment of neural conditions using at least one recipe for a treatment strategy guided by artificial intelligence.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

A radiation treatment device comprises a radiation source layer comprising a radiation source and a controller. The radiation source is configured to emit radiation with a wavelength in the range 822 nm to 1322 nm. In a preferred embodiment, the device configured to emit radiation with a wavelength of 1067 to 1077 nm.

A transcranial stimulator includes a main body formed in a shape that covers part or all of a head surrounding a skull, a light emission module configured in the main body to transmit light energy to a brain, and a controller configured to control an operation of the light emission module, wherein the light emission module includes a first optical device emitting light in a wavelength band of 630 nm to 680 nm toward the skull and a second optical device emitting light in a wavelength band of 780 nm to 990 nm toward the skull.

A device for eradicating at least one pathogen in a nasal passage of a human or animal may include a housing configured to be inserted into the nasal passage, at least one radiation source, configured to emit radiation, coupled to the housing such that at least a portion of a radiation emitting surface, upon insertion of the housing into the nasal passage, faces at least a portion of nasal lining of the nasal passage, and an electrical circuit carried by the housing and electrically connected to the at least one radiation source, the electrical circuit including at least one circuit component for controlling the at least one radiation source to emit the radiation to irradiate the nasal passage, the emitted radiation having a frequency or range of frequencies at which the at least one pathogen in the nasal passage, when irradiated by the emitted radiation, is eradicated.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

A device and method for therapeutically treating conditions using electromagnetic radiation (EMR) is described herein. EMR, of optimal wavelengths and at surprisingly low energy levels, are pulsed for a time duration when aimed at an area of interest, the outcome being an improvement in the condition while not doing damage to surrounding tissue.

The present application discloses a LED therapeutic device comprising a top case, a light assembly, a controller, a switch assembly, a bottom case and a power supply. The light assembly comprises a lens and a LED assembly, wherein the lens is coupled to the top case and the LED assembly comprises three visible light LEDs and two infrared LEDs. Wavelengths of the three visible light LEDs are 470 nm, 630 nm and 660 nm. Wavelengths of the two infrared LEDs are 850 nm and 940 nm. The controller is coupled to the light assembly. The switch assembly is coupled to the controller. The bottom case is removably coupled to the top case. The power supply is electrically coupled to the controller.

The present application discloses a LED therapeutic device comprising a top case, a light assembly, a controller, a switch assembly, a bottom case and a power supply. The light assembly comprises a lens and a LED assembly, wherein the lens is coupled to the top case and the LED assembly comprises at least one visible light LED and at least one infrared LED. The controller is coupled to the light assembly. The switch assembly is coupled to the controller. The bottom case is removably coupled to the top case. The power supply is electrically coupled to the controller.

A self-administrable system for improved immunity and treatment of respiratory tract infections in a subject, said system comprising: a configured irradiation unit for delivery of light energy into at least one portion of an in-vivo target selected from the group consisting of the thymus gland, sternal bone marrow and lungs.